-
Innovation Ranking
NewInnovation Ranking – SMA Solar Technology AG
SMA Solar Technology AG (SMA) is a renewable energy company. It develops, produces, and distributes photovoltaic inverters, choke coils, transformers, and monitoring and energy management systems for PV systems. It also offers intelligent energy management system and digital services, as well as solar power plant operation and maintenance. It serves customers in South America, Asia Pacific, North America, Europe, the Middle East, and Africa. Its R&D efforts focus on developing complete system solutions and digital business models. The company has...
-
Product Insights
NewLikelihood of Approval Analysis for Spinal Muscular Atrophy (SMA)
Overview How likely is it that the drugs in Spinal Muscular Atrophy (SMA) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spinal Muscular Atrophy (SMA) Overview Spinal muscular atrophy (SMA) is...
-
Product Insights
Spinal Muscular Atrophy (SMA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Muscular Atrophy (SMA) - Drugs In Development, 2023’, provides an overview of the Spinal Muscular Atrophy (SMA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Company Insights
Innovation and Patenting activity of SMA Solar Technology AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of SMA Solar Technology AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vartocell in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vartocell in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Vartocell in Spinal Muscular Atrophy (SMA)Drug Details:Vartocell is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talditercept Alfa in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talditercept Alfa in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talditercept Alfa in Spinal Muscular Atrophy (SMA) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6237 in Spinal Muscular Atrophy (SMA)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6237 in Spinal Muscular Atrophy (SMA) Drug Details: RG-6237 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMDP-02 in Spinal Muscular Atrophy (SMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMDP-02 in Spinal Muscular Atrophy (SMA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMDP-02 in Spinal Muscular Atrophy (SMA) Drug Details: NMDP-02 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BIIB-115 in Spinal Muscular Atrophy (SMA)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-115 in Spinal Muscular Atrophy (SMA) Drug Details: BIIB-115 is under development for the treatment of...